Ignite Creation Date:
2025-12-24 @ 1:15 PM
Ignite Modification Date:
2026-01-24 @ 6:06 PM
Study NCT ID:
NCT05361395
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-25
First Post:
2022-04-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sponsor:
Amgen
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Extensive Stage Small Cell Lung Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Extensive Stage Small Cell Lung Cancer | View |
| None | ES-SCLC | View |
| None | SCLC | View |
| None | Lung Cancer | View |
| None | AMG 757 | View |
| None | Bi-Specific T-Cell Engager | View |
| None | BiTE | View |
| None | Inmunotherapy | View |
| None | Immunooncology | View |
| None | Inmuno-oncology | View |
| None | DLL3 | View |
| None | Delta Like Protein 3 | View |